Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04774952 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
A Phase 1 study, sponsored by Revolution Medicines.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT04774952 is a Phase 1 study that has completed, run by Revolution Medicines. The registered enrollment target is 58 participants.
The verdict
NCT04774952, a Phase 1 study, has completed, sponsored by Revolution Medicines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).
Interventions
- DRUG RMC-5552
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-04-07 |
| Est. Completion | 2024-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04774952
The ClinicalTrials.gov registry entry for NCT04774952 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RMC-5552 is the first listed.
NCT04774952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04774952 about?
NCT04774952 is a clinical study titled "Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).
What is the current status of trial NCT04774952?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2021-04-07. Estimated completion is 2024-06-28.
What interventions are being tested in trial NCT04774952?
The interventions under investigation include: RMC-5552 (DRUG).
Who is sponsoring clinical trial NCT04774952?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.